UNITED STATES SECURITIES AND EXCHANGE COMMISSION April 2, 2018

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Titan Pharmaceuticals, Inc.

File No. 001-13341 - CF#36162

Titan Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 8-K filed on March 26, 2018.

Based on representations by Titan Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit will not be released to the public for the time period specified:

Exhibit 10.2 through March 21, 2027

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary